GSK to buy Sierra Oncology for $1.9 billion in boost to blood cancer ops By Reuters


© Reuters. GSK logo is seen in this illustration taken on January 17, 2022. REUTERS/Dado Ruvic/Illustration

(Reuters) -Britain’s GlaxoSmithKline (NYSE:) has agreed to buy California-based biopharmaceutical company Sierra Oncology (NASDAQ:) in a cash deal valued at $1.9 billion, the companies said on Wednesday, as it seeks to bolster its blood cancer business.

Shareholders in Sierra, which focuses on targeted therapies for the treatment of rare forms of cancer, will receive $55 per share of common stock in cash, GSK said.

That’s a 39% premium to Tuesday’s closing price and about two thirds more than the volume-weighted average price (VWAP) over the last 30 trading days, it said.

The deal comes as Sierra prepares to apply in the second quarter for U.S. marketing approval for its experimental drug momelotinib, used to treat anaemic patients with a type of bone marrow cancer.

Data from a late-stage clinical trial showed in January it was successful in reducing disease symptoms and also cut patients’ dependence on blood transfusions.

The acquisition will complement GSK’s multiple myeloma treatment, Blenrep, GSK said. Myeloma is a type of blood cancer that develops from cells in the bone marrow called plasma cells.



Source link

Related articles

Ecovacs’ Black Friday Deal Wipes $401 Off X12S OmniCyclone

Save $401: The Ecovacs Deebot X12S OmniCyclone is on sale for $899 throughout Amazon’s Black Friday sale occasion. This premium robotic vacuum-and-mop combo often retails for $1,300, however it can save you $401...

Coinbase Entered Prediction Markets With Kalshi. Now It Plans to Develop into a Rival

FX Brokers Chase Consumer E-book Offers; XTB Sinks on Poland's CFD Curbs FX Brokers Chase Consumer E-book Offers; XTB...

Abercrombie & Fitch Q3 Preview: A Robust Quarter That Might Not Transfer The Needle

This text was written byObserveI'm a inventory analyst with over 20 years of expertise in quantitative analysis, monetary modeling, and danger administration. My focus is on fairness valuation, market traits, and portfolio optimization...

Borr Drilling declares Prospector 5 a complete loss, with $200 million insured worth

(WO) – Borr Drilling has declared the Prospector 5 jackup a complete loss...
spot_img

Latest articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

WP2Social Auto Publish Powered By : XYZScripts.com